MedinCell climbs 5% following the pharmaceutical company's presentation of positive results for the SAIVE clinical study, conducted on 399 participants in the prevention of Covid-19 infection in a population of contact cases.

This study was conducted in support of the mdc-TTG program, aimed at preventing infection for weeks or months, with a single injection of a long-acting formulation of ivermectin, based on MedinCell's BEPO technology.

It met its primary efficacy endpoint with a 72% reduction in infections in the daily oral ivermectin group, compared with placebo, with acceptable safety and tolerability, and no unexpected safety signals.

Copyright (c) 2023 CercleFinance.com. All rights reserved.